Drug Trial Radar · NCT07114601
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
421
Planned (sponsor's estimate)
Start
Aug 6, 2025
Primary completion
Apr 2030
Study completion Apr 2035
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Aug 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor (GRPR)-positive advanced cancer, including but not limited to breast, colorectal, prostate, endometrial, esophageal, gastroesophageal (GE) junction, and gastric cancer. The study will also evaluate the safety, tolerability, and efficacy of LY4257529 to identify cancer with high levels of a protein called GRPR. This is a 2-part study. Participation could last up to 36 weeks or until your tumor progresses.
Conditions
- Breast Neoplasms
- Colorectal Neoplasms
- Prostate Neoplasm
- Endometrial Neoplasms
- Neoplasm Metastasis
- Stomach Neoplasms
- Esophageal Neoplasms
Interventions
LY4257496Drug
Administered IV
Standard of Care Anticancer TherapiesDrug
Fulvestrant, Imlunestrant, Aromatase Inhibitors, Capecitabine, Abemaciclib
LY4257529Diagnostic test
Administered IV at select sites
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1a Dose Escalation: Maximum Tolerated Dose of LY4257496Time frame: From Cycle 1 Day 1 (C1D1) through 28 days after the first dose of study drug. Cycle = 28 days
- Phase 1a Dose Optimization: Number of Dose Limiting Toxicities of LY4257496Time frame: From Cycle 1 Day 1 (C1D1) through 28 days after the first dose of study drug. Cycle = 28 days
- Phase 1b Dose Expansion and Optimization: Objective Response Rate (ORR): Percentage of Participants with Best Response of Complete Response (CR) or Partial Response (PR)Time frame: From C1D1 through efficacy follow-up, estimated as Week 42. Cycle = 42 weeks
Locations
33 sites in 7 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California · Recruiting
University of California, Los Angeles (UCLA)
Santa Monica, California · Recruiting
Stanford University Medical Center
Stanford, California · Recruiting
Biogenix Molecular, LLC
Miami, Florida · Active not recruiting
Moffitt
Tampa, Florida · Recruiting
Emory University School of Medicine - Winship Cancer Institute
Atlanta, Georgia · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Not yet recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan · Recruiting
BAMF Health Inc.
Grand Rapids, Michigan · Recruiting
Washington University
St Louis, Missouri · Recruiting
New York University (NYU) Langone Medical Center
New York, New York · Not yet recruiting
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania · Not yet recruiting
Texas Oncology - DFW (Sammons CC)
Dallas, Texas · Not yet recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Juravinski Cancer Centre
Hamilton, Canada · Recruiting
Lady Davis Institute for Medical Research Jewish General Hospital
Montreal, Canada · Not yet recruiting
Sunnybrook Health Sciences Centre
Toronto, Canada · Recruiting
Princess Margaret Hospital
Toronto, Canada · Recruiting
Peking Union Medical College Hospital of Chinese Academy of Medical Sciences
Beijing, China · Not yet recruiting
Tianjin Cancer Hospital Airport Hospital
Tianjin, China · Not yet recruiting
Institut Curie
Paris, France · Not yet recruiting
Institut de Cancerologie de l'Ouest - site St-Herblain
Saint-Herblain, France · Not yet recruiting
Universitaetsklinikum Erlangen
Erlangen, Germany · Not yet recruiting
Universitaetsklinikum Essen
Essen, Germany · Recruiting
LMU Klinikum Muenchen-Campus Grosshadern
München, Germany · Not yet recruiting
Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)
München, Germany · Not yet recruiting
National Cancer Center Hospital East
Chiba, Japan · Not yet recruiting
Kyoto University Hospital
Kyoto, Japan · Not yet recruiting
The University of Osaka Hospital
Osaka, Japan · Not yet recruiting
Hospital Universitari Quiron Dexeus Barcelona
Barcelona, Spain · Not yet recruiting
South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz
Madrid, Spain · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.